efficacy and low incidence of side effects from this treatment. -5 Two further papers appeared in the November issue of the Annals.6 7 The paper by Walters and Cawley showed the value of combining pulse methylprednisolone with sodium aurothiomalate treatment,6 results similar to our findings in a previous publication, of which the authors appeared not to be aware. 3 The paper by Williams et al again showed the low incidence of adverse effects from this treatment and, more specifically, failed to find an increased incidence of avascular necrosis of the femoral head, which theoretically would be an expected adverse effect in view of the large doses of corticosteroid used in pulse methylprednisolone therapy.7 1though this retrospective cohort study needs to be confirmed by a prospective long term study with large patient numbers as well as matched controls, it confirms the favourable risk/benefit ratio of this treatment. It is therefore surprising that our papers on this subject in another journalP5 led to an editorial comment' and correspondence9 '0 describing this treatment as 'ineffective' and 'hardly justifiable' in the treatment of rheumatoid arthritis. Perhaps this simply reflects a conservative attitude ofNorth American clinicians, yet it is surprising that pulse therapy, with its favourable risk/benefit ratio, considerable efficacy in short term control of inflammation, and efficacy as oral treatment,"n should not be at least as attractive a therapeutic option as the alternatives-namely, non-steroidal anti-inflammatory drugs (low efficacy, high incidence of adverse effects) and disease modifying antirheumatic drugs (slow onset of action, high incidence of adverse effects, high drop out rate). None of the recent publications has advocated pulse therapy as an alternative to remittive agents, but rather as adjunctive treatment to achieve rapid control of inflammation while awaiting control with a remittive agent, or in the event of failed treatment with several disease modifying antirheumatic drugs.
Perhaps it is time for a Viewpoint article in the Annals on the place of pulse methylprednisolone therapy in the treatment of rheumatoid arthritis, lest a potentially useful treatment should be neglected as a result of therapeutic conservatism. 5 There was a feeling at the consensus meeting before the viewpoint article that less weight should now be given to radiological assessments. That is not to deny their relevance nor to overlook the valuable work contributed by Dr Larsen in this field. Clearly, rheumatological ideas move on, and this certainly happened with the views expressed in the viewpoint article on the value of x rays. Ten years ago many rheumatologists were convinced that plain radiology provided the gold standard to assess the progression of rheumatoid arthritis. It takes time for such views to become less pronounced, but the moment has now arrived. Clinical trials usually reflect the prevailing opinions when they were set up and so it is hardly surprising that recently published trials of antirheumatic drugs have used x rays, but in future their use may be more restricted.
There are no methods of assessing RA which are appropriate in all circumstances, but there is a need for new approaches; this need lay at the heart of the viewpoint article. 
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